December 19, 2016 / 1:57 PM / 7 months ago

BRIEF-Ampliphi Biosciences reports favorable final results from phase 1 trial of AB-SA01

1 Min Read

Dec 19 (Reuters) - Ampliphi Biosciences Corp :

* Primary endpoints of safety and tolerability were met

* Ampliphi biosciences reports favorable final results from phase 1 trial of AB-SA01 in chronic rhinosinusitis patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below